pairb

Olaparib (Olaparib) instructions

Common name: Olaparib

Trade name: Olaparib

All names: Olaparib, Olaparib, Olaparib, Lynparza, Olanib, Olaparix, Lynib

Olaparib indications and uses

Lynparza is a polyadenosine diphosphate ribose polymerase (PARP) inhibitor.

1. It is suitable for single-agent treatment in patients with BRCA advanced ovarian cancer with harmful or suspected harmful germline mutations who have been treated with 3 or more previous lines of chemotherapy.

2. For the treatment of germline BRCA gene mutation, HER2-negative metastatic breast cancer, and the patient has previously received neoadjuvant, adjuvant or metastatic breast cancer chemotherapy.

Olaparib dosage and administration

⑴The recommended dose is 400 mg twice a day.

⑵ Continue treatment until disease progression or unacceptable toxicity.

⑶ For adverse reactions, consider interrupting or reducing the dose of treatment.

Olaparib contraindications

None.

Olaparib Warnings and Precautions

⑴ Myelodysplastic syndrome/acute myeloid leukemia: (MDS/AML) occurs in patients exposed to Lynparza, and some cases are fatal. Monitor patients for hematologic toxicity at baseline and monthly thereafter. MDS/AML terminated if confirmed.

⑵Pneumonia: Occurring in patients exposed to Lynparza and in some cases fatal. Interrupt treatment if pneumonia is suspected. Terminate upon confirmation.

⑶Embryo-fetal toxicity: Lynparza can cause fetal harm. Advise women of childbearing potential of the potential hazard to the fetus and to avoid pregnancy.

Olaparib Adverse Reactions

⑴ The most common adverse reactions (≥20%) in clinical trials are anemia, nausea, fatigue (including asthenia), vomiting, diarrhea, dysgeusia, dyspepsia, headache, loss of appetite, nasopharyngitis/pharyngitis/URI, cough, arthralgia/musculoskeletal pain, myalgia, back pain, dermatitis/rash and abdominal pain/discomfort.

⑵ The most common laboratory abnormalities (≥25%) are increased creatinine, increased mean red blood cell volume, decreased hemoglobin, lymphopenia, decreased absolute neutrophil count, and thrombocytopenia.

Olaparib drug interactions

⑴CYP3A inhibitors: Avoid the simultaneous use of strong and moderate CYP3A inhibitors. If inhibitors cannot be avoided, reduce dose.

⑵CYP3A inducers: Avoid the simultaneous use of strong and moderate CYP3A inducers. If moderate CYP3A inducers cannot be avoided, it is recognized that the potential for reduced efficacy is reduced.

Olaparib use in special populations

Breastfeeding mothers: Discontinue treatment or discontinue breastfeeding.